Mathematical models of the build-up and depletion of the hypnozoite reservoir in the liver can inform the design of treatment strategies for preventing Plasmodium vivax relapse infections.

In silico modelling of all available data shows that a twenty-day ascending-dose primaquine regimen could be safe to administer to G6PD deficient patients for the radical cure of vivax malaria.

This comprehensive transcriptomic resource of dormant and replicating malaria liver parasites highlights the dearth of pathways that operate in the hypnozoites and the need to investigate druggability (i.e. selectivity and safety) of core pathways in malaria parasites.

Transcriptome profiling of malaria liver-stage parasites provides unprecedented knowledge on genes and pathways expressed in truly dormant hypnozoites and indicates that dormancy is associated with a switch in energy metabolism.

LISP2 expression marks the beginning of awakening of dormant hypnozoite to developing malaria liver stages, which are susceptible to a novel prophylactic drug, Plasmodium PI4K inhibitor.

The currently recommended adult dose of tafenoquine is insufficient for radical cure in all adults.

A full radical curative dose of primaquine can be given to fully glucose-6-phosphate dehydrogenase-deficient males safely using an ascending dose regimen.

We are writing to comment on the article by Watson et al., 2022 about the antimalarial drug tafenoquine.

We are writing to respond to comment by Sharma et al, 2024 on our article about the antimalarial drug tafenoquine.